Papers published on a yearly basis
Papers
More filters
••
Harvard University1, Fox Chase Cancer Center2, University of Michigan3, Memorial Sloan Kettering Cancer Center4, University of Pennsylvania5, University of Iowa6, Stanford University7, University of Pittsburgh8, Washington University in St. Louis9, St John of God Health Care10, Janssen Pharmaceutica11, Icahn School of Medicine at Mount Sinai12, University of Texas MD Anderson Cancer Center13
TL;DR: Because disease control in advanced sarcomas is a clinically relevant end point, this study supports the activity of trabectedin for patients with these malignancies.
Abstract: PurposeThis multicenter study, to our knowledge, is the first phase III trial to compare trabectedin versus dacarbazine in patients with advanced liposarcoma or leiomyosarcoma after prior therapy with an anthracycline and at least one additional systemic regimen.Patients and MethodsPatients were randomly assigned in a 2:1 ratio to receive trabectedin or dacarbazine intravenously every 3 weeks. The primary end point was overall survival (OS), secondary end points were disease control—progression-free survival (PFS), time to progression, objective response rate, and duration of response—as well as safety and patient-reported symptom scoring.ResultsA total of 518 patients were enrolled and randomly assigned to either trabectedin (n = 345) or dacarbazine (n = 173). In the final analysis of PFS, trabectedin administration resulted in a 45% reduction in the risk of disease progression or death compared with dacarbazine (median PFS for trabectedin v dacarbazine, 4.2 v 1.5 months; hazard ratio, 0.55; P < .001); b...
604 citations
••
TL;DR: The Position Statement wishes to contribute to a more cost-effective approach to the care of patients with BE by reducing the number of surveillance endoscopies for patients with a low risk of malignant progression and centralizing care in expert centers for those with high progression rates.
Abstract: Current practices for the management of Barrett’s esophagus (BE) vary across Europe, as several national European guidelines exist. This Position Statement from the European Society of Gastrointestinal Endoscopy (ESGE) is an attempt to homogenize recommendations and, hence, patient management according to the best scientific evidence and other considerations (e.g. health policy). A Working Group developed consensus statements, using the existing national guidelines as a starting point and considering new evidence in the literature. The Position Statement wishes to contribute to a more cost-effective approach to the care of patients with BE by reducing the number of surveillance endoscopies for patients with a low risk of malignant progression and centralizing care in expert centers for those with high progression rates. Main statements MS1 The diagnosis of BE is made if the distal esophagus is lined with columnar epithelium with a minimum length of 1 cm (tongues or circular) containing specialized intestinal metaplasia at histopathological examination. MS2 The ESGE recommends varying surveillance intervals for different BE lengths. For patients with an irregular Z-line/columnar-lined esophagus of MS3 The diagnosis of any degree of dysplasia (including “indefinite for dysplasia”) in BE requires confirmation by an expert gastrointestinal pathologist. MS4 Patients with visible lesions in BE diagnosed as dysplasia or early cancer should be referred to a BE expert center. All visible abnormalities, regardless of the degree of dysplasia, should be removed by means of endoscopic resection techniques in order to obtain optimal histopathological staging MS5 All patients with a BE ≥ 10 cm, a confirmed diagnosis of low grade dysplasia, high grade dysplasia (HGD), or early cancer should be referred to a BE expert center for surveillance and/or treatment. BE expert centers should meet the following criteria: annual case load of ≥10 new patients undergoing endoscopic treatment for HGD or early carcinoma per BE expert endoscopist; endoscopic and histological care provided by endoscopists and pathologists who have followed additional training; at least 30 supervised endoscopic resection and 30 endoscopic ablation procedures to acquire competence in technical skills, management pathways, and complications; multidisciplinary meetings with gastroenterologists, surgeons, oncologists, and pathologists to discuss patients with Barrett’s neoplasia; access to experienced esophageal surgery; and all BE patients registered prospectively in a database.
424 citations
••
TL;DR: Endoscopic therapy is highly effective and safe for patients with mAC, with excellent long-term results; in an almost 5-year follow-up of 1000 patients treated with endoscopic resection, there was no mortality and less than 2% had major complications.
394 citations
••
University of California1, Duke University2, University of Glasgow3, University of Brescia4, Harvard University5, University of North Carolina at Chapel Hill6, University of Minnesota7, University of Copenhagen8, Saarland University9, Medical University of Vienna10, Imperial College London11, Pontifical Catholic University of Chile12, Linköping University13, University of Utah14, National and Kapodistrian University of Athens15, Nova Southeastern University16, Comenius University in Bratislava17, Sofia Medical University18, Henry Ford Hospital19, Peking Union Medical College20, Middlemore Hospital21, St. Vincent's Health System22, Moscow State University23, Université de Montréal24, Wrocław Medical University25, University of São Paulo26, Vilnius University27, University of Cape Town28, Masaryk University29, University Hospital of Bern30, St John of God Health Care31, Carol Davila University of Medicine and Pharmacy32, University of Groningen33, Dokuz Eylül University34, University of Lorraine35, Amgen36
TL;DR: Among patients with heart failure and a reduced ejection, patients who received omecamtiv mecarbil had a lower incidence of a composite of a heart-failure event or death from cardiovascular causes than those who received placebo.
Abstract: Background The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardiac function in patients with heart failure with a reduced ejection fraction. Its effect ...
341 citations
••
TL;DR: Complications after PNL can be kept to a minimum in experienced hands with the development of new techniques and improved technology and a modified procedure-specific Clavien classification should be established that would need to be validated in prospective trials.
320 citations
Authors
Showing all 574 results
Name | H-index | Papers | Citations |
---|---|---|---|
Colm McDonald | 62 | 294 | 23778 |
Leon Straker | 61 | 407 | 13966 |
Mark A. Kotowicz | 60 | 271 | 12768 |
Cornel C. Sieber | 57 | 300 | 20744 |
Marie-Paule Austin | 55 | 165 | 10379 |
Paul Fearon | 55 | 159 | 8918 |
Eadbhard O'Callaghan | 53 | 178 | 16016 |
Zachary Steel | 52 | 170 | 13038 |
Yee Leung | 50 | 275 | 9202 |
Christobel Saunders | 48 | 332 | 8939 |
Veronica O'Keane | 46 | 150 | 7084 |
David Cotter | 45 | 144 | 7111 |
Oliver Pech | 44 | 201 | 8296 |
Majella Byrne | 43 | 88 | 5170 |
Mary Clarke | 43 | 199 | 6149 |